Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 15/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22577407 | 0.89 | CYP3A4 (0.62) | CYP3A4CYP2D6ADORA2A | |
| SCHEMBL22577416 | 0.83 | CYP3A4 (0.62) | CYP3A4CYP2D6 | |
| SCHEMBL22577403 | 0.80 | CYP3A4 (0.65) | CYP3A4CYP2D6 | |
| SCHEMBL29211967 | 0.79 | CYP3A4 (0.67) | CYP3A4CYP2D6ADORA2AADORA1 | |
| SCHEMBL29211966 | 0.79 | CYP3A4 (0.67) | CYP3A4CYP2D6ADORA2AADORA1 | |
| SCHEMBL30931874 | 0.79 | CYP3A4 (0.67) | CYP3A4CYP2D6ADORA2AADORA1 | |
| SCHEMBL30931891 | 0.79 | CYP3A4 (0.67) | CYP3A4CYP2D6ADORA2AADORA1 | |
| Ammonia Solution, Strong SCHEMBL29626970 | 0.77 | CYP3A4 (0.65) | CYP3A4CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL29626966 | 0.77 | CYP3A4 (0.65) | CYP3A4CYP2D6 | |
| SCHEMBL22577390 | 0.76 | CYP3A4 (0.57) | CYP3A4CYP2D6ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3730503-B1 | ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | SHENZHEN TARGETRX INC (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-20220389038-A1 | ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | SHENZHEN TARGETRX, INC. (CN) | 2022-12-08 | — | — | US | disclosed |
| US-11447512-B2 | Antiviral nucleoside reverse transcriptase inhibitor | SHENZHEN TARGETRX, INC. (CN) | 2022-09-20 | — | — | US | disclosed |
| US-20200369696-A1 | ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | SHENZHEN TARGETRX, INC. (CN) | 2020-11-26 | — | — | US | disclosed |
| EP-3730503-A1 | ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | Shenzhen TargetRx, Inc. (CN) | 2020-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369696-A1 | ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | TYMP, HPRT1, POLRMT | CYP3A4 381/4885CYP2D6 293/4885ADORA2A 3606/4885 |
| US-11447512-B2 | Antiviral nucleoside reverse transcriptase inhibitor | TYMP, HPRT1, POLRMT | CYP3A4 381/4885CYP2D6 293/4885ADORA2A 3606/4885 |
| US-20220389038-A1 | ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | TYMP, HPRT1, POLRMT | CYP3A4 381/4885CYP2D6 293/4885ADORA2A 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.